The 36-month beta value for PLRX is also noteworthy at 1.36. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 10 rating it as “hold,” and 0 rating it as “sell.”
The public float for PLRX is 54.04M, and at present, short sellers hold a 7.26% of that float. The average trading volume of PLRX on June 20, 2025 was 1.09M shares.
PLRX) stock’s latest price update
Pliant Therapeutics Inc (NASDAQ: PLRX)’s stock price has plunge by -2.67relation to previous closing price of 1.31. Nevertheless, the company has seen a -13.27% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-21 that SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025.
PLRX’s Market Performance
PLRX’s stock has fallen by -13.27% in the past week, with a monthly drop of -6.93% and a quarterly drop of -19.30%. The volatility ratio for the week is 2.76% while the volatility levels for the last 30 days are 4.21% for Pliant Therapeutics Inc The simple moving average for the last 20 days is -10.92% for PLRX stock, with a simple moving average of -83.67% for the last 200 days.
PLRX Trading at -11.51% from the 50-Day Moving Average
After a stumble in the market that brought PLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.08% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLRX starting from Coulie Bernard, who sale 52,419 shares at the price of $11.20 back on Jan 17 ’25. After this action, Coulie Bernard now owns 430,517 shares of Pliant Therapeutics Inc, valued at $587,150 using the latest closing price.
Cummings Keith Lamont, the Chief Financial Officer of Pliant Therapeutics Inc, sale 20,148 shares at $11.20 during a trade that took place back on Jan 17 ’25, which means that Cummings Keith Lamont is holding 262,608 shares at $225,680 based on the most recent closing price.
Stock Fundamentals for PLRX
The total capital return value is set at -0.74. Equity return is now at value -63.22, with -50.67 for asset returns.
Based on Pliant Therapeutics Inc (PLRX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.89. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -69.54.
Currently, EBITDA for the company is -228.37 million with net debt to EBITDA at 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.03.
Conclusion
In summary, Pliant Therapeutics Inc (PLRX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
